LOS ANGELES, April 29, 2005 (PRIMEZONE) -- BiomedDiscoveries.com, http://www.BiomedDiscoveries.com, the online source for exclusive investor information in the biotechnology sector, has announced the availability of an online interview with Xenomics Chairman and founder Dr. David Tomei, and Dr. Randy White, CEO of Xenomics (OTCBB:XNOM), a molecular diagnostics company.
In the audio interview, Dr. Tomei provides an overview of Xenomics' revolutionary HIV-DNA detection methodology using the Company's proprietary trans-renal DNA (Tr-DNA) technology. Scientists from Xenomics were the first to report that fragments of DNA from inside the body cross the kidney barrier and can be detected in urine. The Company is applying this discovery to the development of tests for prenatal genetic testing and to detect infectious disease and other conditions using simple, inexpensive and completely non-invasive urine sample testing.
Xenomics has recently reported on the ability of its proprietary Tr-DNA to detect HIV DNA in the urine of HIV-positive patients, potentially enabling additional diagnostic information for physicians treating AIDS patients with residual disease where traditional viral load testing is barely detectable, or in many cases undetectable. "The sensitivity of our development-stage test is capable of detecting as few as five viral particles, or genome equivalents, in the urine of treated AIDS patients. As we continue our development we expect that sensitivity to increase," said Dr. Tomei.
In collaboration with the Spallanzani Institute in Rome, a large AIDS treatment center in Italy with more than 4,000 AIDS patients, the Company is preparing to start clinical studies, the next phase in commercial development of their technologies. "These clinical studies are necessary to increase the number of patients involved so that we can obtain more information about how patients respond to therapy, and of course how the Tr-DNA testing can track the patients' response," said Dr. Tomei. "We're in the process now of what they call 'optimizing the method' -- increasing its efficiency and accuracy. We're looking forward to very high sensitivity that will approach 100%."
Dr. White discussed the size of the potential markets for this non-invasive method for early and highly sensitive detection of HIV-DNA, along with the unique capabilities of the Xenomics technology to monitor for residual HIV disease in patients that have a viral load too low to be detectable with current blood test methods.
The streaming audio interview can be accessed at http://www.BiomedDiscoveries.com. Registration to listen to the interview is free.
About Xenomics, Inc.
Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA (Tr-DNA). Xenomics' patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. Scientists from Xenomics were the first to report that fragments of DNA from normal cell death cross the kidney barrier and can be detected in urine. The Company believes that its technology will open significant new markets in the molecular diagnostics field. Xenomics has three issued U.S. patents covering different applications of the technology for molecular diagnostics and genetic testing and a pending European patent for the same applications. The Company has organized a joint venture to conduct research on infectious disease detection with the National Institute for Infectious Diseases (Instituto Nazionale per le Malattie Infettive "Lazarus Spallanzani") in Rome, in the form of a new R&D company called SpaXen Italia, S.R.L. For more information, please visit http://www.trilogy-capital.com/tcp/xenomics/website.html. For more investor-specific information, including daily and historical Company stock quote data and recent news releases, please visit http://www.trilogy-capital.com/tcp/xenomics. To read or download the Company's Investor Fact Sheet visit http://www.trilogy-capital.com/tcp/xenomics/factsheet.html. To view an online video about Xenomics technology and products, visit http://www.trilogy-capital.com/tcp/xenomics/video.html. A TV news report about the Company's next-generation prenatal tests can be viewed at http://www.trilogy-capital.com/tcp/xenomics/ny1_video.html.
About BiomedDiscoveries.com
BiomedDiscoveries.com provides exclusive commentary, research, interviews and other information about the smallcap investment marketplace. BiomedDiscoveries.com strives to provide investors with information and research-based data regarding important individual companies and overall marketplace trends. Resources available on BiomedDiscoveries.com include audio interviews with corporate leaders and respected commentators, as well as technical white papers and other forms of market and investment analysis. It is located at http://www.BiomedDiscoveries.com.
Forward-Looking Statements
Statements made on BiomedDiscoveries.com may contain forward-looking statements made by senior management of the companies presented here that involve risks and uncertainties, such as statements about plans, objectives, expectations, assumptions or future events. These statements involve estimates, assumptions, known and unknown risks, uncertainties and performances, or achievements expressed or implied by the forward-looking statements. Actual future results and trends may differ materially from those made in -- or suggested by -- statements presented here due to a variety of factors. Consequently, you should not place undue reliance on any forward-looking statements made here. Many of these and other risks and uncertainties are discussed in greater detail in recent filings with the Securities Exchange Commission for the companies that are present by BiomedDiscoveries.com. Compensation and Other Disclosures BiomedDiscoveries.com is a wholly-owned subsidiary of Trilogy Capital Partners, Inc. Trilogy Capital Partners provides investor relations services to public companies. The companies presented by BiomedDiscoveries.com are usually clients of Trilogy Capital Partners and compensate Trilogy Capital Partners for these services, including cash compensation and equity securities. In addition, Trilogy Capital Partners and its affiliates may own securities of the presenting companies, and may from time to time purchase and sell securities of these companies in the open market or in private transactions. Trilogy receives compensation from Xenomics of $10,000 per month through January 2006 and thereafter for so long as Trilogy is retained to provide investor relations services.
The Company issued Trilogy warrants to purchase 1,000,000 shares of Common Stock of the Company at an exercise price of $2.95 per share (the "Warrants"). The Warrants issued to Trilogy are exercisable upon issuance and expire on January 10, 2008. In the event the Company proposes to register any of its Common Stock under the Securities Act of 1933 for sale in connection with a public offering of Common Stock, the Company will give written notice to Trilogy and will include in such registration statement any of the shares of Common Stock underlying the Warrants which Trilogy may request be included. The offer and sale of these securities was made in reliance on Section 4(2) of the Securities Act of 1933, as amended. The offer and sale of the Warrants did not involve a public offering.